首页> 美国卫生研究院文献>Saudi Pharmaceutical Journal : SPJ >Formulation development and optimization of sustained release matrix tablet of Itopride HCl by response surface methodology and its evaluation of release kinetics
【2h】

Formulation development and optimization of sustained release matrix tablet of Itopride HCl by response surface methodology and its evaluation of release kinetics

机译:响应面分析法开发盐酸依托必利缓释基质片的配方开发与优化及其释放动力学评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this present investigation was to develop and formulate sustained release (SR) matrix tablets of Itopride HCl, by using different polymer combinations and fillers, to optimize by Central Composite Design response surface methodology for different drug release variables and to evaluate drug release pattern of the optimized product. Sustained release matrix tablets of various combinations were prepared with cellulose-based polymers: hydroxy propyl methyl cellulose (HPMC) and polyvinyl pyrolidine (pvp) and lactose as fillers. Study of pre-compression and post-compression parameters facilitated the screening of a formulation with best characteristics that underwent here optimization study by response surface methodology (Central Composite Design). The optimized tablet was further subjected to scanning electron microscopy to reveal its release pattern. The in vitro study revealed that combining of HPMC K100M (24.65 MG) with pvp(20 mg)and use of LACTOSE as filler sustained the action more than 12 h. The developed sustained release matrix tablet of improved efficacy can perform therapeutically better than a conventional tablet.
机译:本研究的目的是通过使用不同的聚合物组合物和填充剂来开发和配制盐酸依托必利的缓释(SR)基质片剂,通过Central Composite Design响应面方法对不同的药物释放变量进行优化,并评估药物的释放方式优化产品的数量。用纤维素基聚合物:羟丙基甲基纤维素(HPMC)和聚乙烯吡咯烷酮(pvp)和乳糖作为填充剂,制备了各种组合的缓释基质片剂。压缩前和压缩后参数的研究有助于筛选具有最佳特性的制剂,此处通过响应面方法(中央复合设计)进行了优化研究。将优化的片剂进一步进行扫描电子显微镜检查以揭示其释放模式。体外研究表明,HPMC K100M(24.65 MG)与pvp(20 mg)的结合以及使用LACTOSE作为填充剂可持续作用超过12小时。已开发的具有改善功效的缓释基质片剂可以在治疗上比常规片剂更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号